2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2456

Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
Abstract Number: 2051

Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis
Abstract Number: 1773

Risk Factors for Cerebrovascular Events in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
Abstract Number: 1181

Risk Factors for Incident Fractures in Patients with Systemic Lupus Erythematosus on Dialysis
Abstract Number: 1798

Risk Factors for Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review
Abstract Number: 773

Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Abstract Number: 2643

Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Abstract Number: 1353

Risk Factors of Pulmonary Mycobacterium Avium-Comlex (MAC) Disease and the Significance of Anti-MAC Antibody in Patients with Rheumatic Diseases
Abstract Number: 2618

Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)
Abstract Number: 683

Risk Factors of Uveitis in Ankylosing Spondylitis
Abstract Number: 896

Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica
Abstract Number: 1496

Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: 1714

Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Abstract Number: 260

Risk of Cardiovascular Disease Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
Abstract Number: 2989

Risk of Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].